SAB Biotherapeutics (SABS) AI Stock Analysis

• Market Cap: $23.51M
• Dividend Yield: N/A
• Average Volume (3M): 2.85M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.63
• Revenue Growth: -85.48%
• EPS Growth: 45.13%
• Country: US
• Employees: 63
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 9,291,697
• 10 Day Avg. Volume: 8,484,476
• 30 Day Avg. Volume: 2,849,933
• PEG Ratio: N/A
• Price to Book (P/B): 1.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.74
• Enterprise Value/Market Cap: 1.05
• Enterprise Value/Revenue: 0.40
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.03
• 1Y Price Target: $11.50
• Price Target Upside: 408.85% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 54 Neutral
• Price Target: $2.50 ▲(10.62%Upside)

SAB Biotherapeutics' overall stock score reflects a challenging financial performance with declining revenues and cash flow issues, offset by a positive technical analysis and significant corporate events, such as the $175 million private placement. Valuation concerns persist due to negative earnings.

Positive Factors

Clinical Trial Progress

The FDA confirmed that the Phase 2b trial could serve as a pivotal trial for approval, aligning with the trial design and eliminating the need for interim analysis.

Competitive Advantage

SAB-142 has a potential competitive dosing regimen with 2-3 days dosing versus 12-14 days with teplizumab, which could be advantageous for outpatient settings.

Strategic Partnership

The strategic investment from Sanofi indicates pharmaceutical interest in SAB-142 and the high unmet need for new treatments in Type 1 Diabetes.

Negative Factors

Clinical Trial Timeline

The Phase 2b SAFEGUARD study in adult and pediatric patients with new-onset stage 3 T1D is anticipated to initiate in mid-2025, indicating progress in clinical development.

SAB Biotherapeutics Business Overview & Revenue Model

Company Description

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

How the Company Makes Money

SAB Biotherapeutics generates revenue primarily through research and development collaborations, government contracts, and grants. The company's revenue streams include milestone payments from strategic partnerships and licensing agreements, where they collaborate with pharmaceutical companies and government agencies to develop and commercialize their antibody-based therapies. Additionally, SAB Biotherapeutics may receive revenue from the sale of its therapeutic products once they gain regulatory approval and enter the market.

SAB Biotherapeutics Financial Statement Overview

Summary

SAB Biotherapeutics faces significant financial challenges, with declining revenues, persistent losses, and cash flow difficulties. The negative cash flow and profitability metrics highlight the need for strategic improvements to achieve financial sustainability.

Income Statement

SAB Biotherapeutics has experienced a significant decline in revenue over recent years, with total revenue falling from $60.88 million in 2021 to just $1.32 million in 2024. The company has maintained negative EBIT and net income, indicating ongoing operational challenges. Margins have remained weak, with a negative net profit margin, reflecting persistent losses.

Balance Sheet

The company's balance sheet shows a relatively high debt-to-equity ratio, indicating a reliance on debt financing. However, the equity ratio remains reasonable, suggesting some level of financial stability. Stockholders' equity has decreased over the years, which could be a concern if this trend continues.

Cash Flow

SAB Biotherapeutics has faced challenges in generating positive operating cash flow, with significant negative free cash flow in recent years. The company has also shown volatility in financing cash flows, suggesting potential difficulties in maintaining liquidity and funding operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.32M	2.24M	23.90M	60.88M	55.24M
Gross Profit	-3.47M	-1.51M	20.61M	59.22M	55.24M
EBITDA	-28.99M	-38.13M	-15.12M	-15.20M	21.14M
Net Income	-34.10M	-42.19M	-18.74M	-17.14M	20.12M
Balance Sheet
Total Assets	44.20M	83.94M	50.90M	79.37M	56.54M
Cash, Cash Equivalents and Short-Term Investments	20.76M	56.57M	15.05M	33.21M	12.61M
Total Debt	4.67M	5.91M	5.93M	6.74M	8.13M
Total Liabilities	18.23M	26.64M	19.85M	40.82M	17.53M
Stockholders Equity	25.97M	57.30M	31.06M	38.55M	39.01M
Cash Flow
Free Cash Flow	-34.63M	-25.32M	-7.19M	-7.19M	-2.73M
Operating Cash Flow	-34.29M	-25.12M	3.76M	3.76M	10.00M
Investing Cash Flow	-11.96M	-152.70K	-10.94M	-10.94M	-12.72M
Financing Cash Flow	-1.17M	66.77M	34.12M	34.12M	8.98M

SAB Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.26
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SABS, the sentiment is Neutral. The current price of 2.26 is below the 20-day moving average (MA) of 2.45, above the 50-day MA of 2.07, and below the 200-day MA of 2.41, indicating a neutral trend. The MACD of 0.12 indicates Positive momentum. The RSI at 47.65 is Neutral, neither overbought nor oversold. The STOCH value of 3.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SABS.

SAB Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SABS	54 Neutral	$23.51M	―	-92.35%	―	-85.48%	45.13%
Sector *	52 Neutral	$7.47B	0.53	-62.70%	2.38%	14.92%	0.82%
IMNN	41 Neutral	$15.30M	―	-397.54%	―	―	24.16%
ERNA	―	$13.18M	―	-2264.31%	―	―	―
BOLT	52 Neutral	$12.08M	―	-83.92%	―	-67.87%	0.40%
MRKR	44 Neutral	$15.95M	―	-97.30%	―	-3.23%	38.05%
INAB	34 Underperform	$7.58M	―	-174.66%	―	―	38.53%

SAB Biotherapeutics Corporate Events

SAB Biotherapeutics Secures $175M in Private Placement

On July 21, 2025, SAB Biotherapeutics announced an oversubscribed $175 million private placement with participation from strategic investor Sanofi and other institutional investors. The proceeds are intended to fully fund the Phase 2b SAFEGUARD study of SAB-142 in Stage 3 autoimmune T1D and extend the company’s cash runway into mid-2028. The private placement includes the issuance of Series B nonvoting convertible preferred stock and warrants, potentially raising an additional $284 million if exercised in full. This financing is expected to bolster SAB’s position in the biopharmaceutical industry by supporting the development of its novel immunotherapy platform.

The most recent analyst rating on (SABS) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.

SAB Biotherapeutics Holds Annual Stockholders Meeting

On July 17, 2025, SAB Biotherapeutics, Inc. held its Annual Meeting of Stockholders, where approximately 71.38% of the outstanding shares were represented. During the meeting, shareholders elected four Class I directors and ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s governance and financial oversight positively.

The most recent analyst rating on (SABS) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.